• Explore /
  • Poster
  • / Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.

Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.

Abstract Poster

Authors

Ali Khaki

Ali Raza Khaki

Stanford University School of Medicine, Division of Oncology, Stanford, CA

Ali Raza Khaki , Alice C. Fan , Sumit Shah , Divya Ahuja Parikh , Joanne Chien , Kaidi Moore , Shann Mika Ruiz , Denise Haas , Laith Fakhoury , Noël Del Toro , Paige Baker , Aidan O'Brien , Sandy Srinivas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer and Urothelial Carcinoma

Track

Urothelial Carcinoma,Prostate Cancer - Advanced

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT03912818

Citation

J Clin Oncol 41, 2023 (suppl 6; abstr 524)

DOI

10.1200/JCO.2023.41.6_suppl.524

Abstract #

524

Poster Bd #

L7

Abstract Disclosures

Similar Posters

First Author: David Shao Peng Tan

First Author: Ali Raza Khaki

First Author: Andrew B Katims

First Author: Feng Wen